Treatment of Influenza A with Wheezing

Antiviral Therapy Selection

The American Academy of Pediatrics recommends oseltamivir 75 mg orally twice daily for 5 days in adults, with a reduced dose of 75 mg once daily if creatinine clearance is <30 mL/min, for patients with influenza A and wheezing 1, 2, 3
Treatment should be initiated in patients with acute influenza-like illness, fever >38°C, and symptom duration ≤2 days, according to the British Thoracic Society 2, 3, 4
For children ≥12 months, weight-based dosing of oseltamivir applies: 30 mg twice daily (≤15 kg), 45 mg twice daily (>15-23 kg), 60 mg twice daily (>23-40 kg), or 75 mg twice daily (>40 kg), as recommended by the American Academy of Pediatrics 1

Immunocompromised or elderly patients may benefit from oseltamivir even without documented fever, as they may not mount adequate febrile responses, according to the British Thoracic Society 1, 2, 3

The British Thoracic Society recommends against routine prescription of antibiotics for previously healthy adults with acute bronchitis and wheezing complicating influenza in the absence of pneumonia 2, 3, 4, 5
Antibiotics should be considered only if worsening symptoms develop, the patient is at high risk for complications or secondary infection, or signs of bacterial pneumonia emerge, according to the British Thoracic Society and the Centers for Disease Control and Prevention 2, 3, 5, 6
Preferred oral antibiotic regimens when indicated include co-amoxiclav or tetracycline as first-line, and macrolides or respiratory fluoroquinolones as alternatives, as recommended by the British Thoracic Society and the Centers for Disease Control and Prevention 2, 3, 4, 5

Hospitalized patients who are severely ill may benefit from oseltamivir even when started >48 hours after symptom onset, particularly if immunocompromised, though evidence is limited, according to the Centers for Disease Control and Prevention and the British Thoracic Society 1, 2, 3, 7
Oseltamivir may reduce mortality when initiated up to 5 days after symptom onset in critically ill patients, particularly those with H1N1, according to the Centers for Disease Control and Prevention 7

High-risk patients, such as the elderly and immunocompromised, should not be withheld from oseltamivir even if presenting slightly beyond 48 hours, as they may still benefit, according to the Centers for Disease Control and Prevention and the American Academy of Pediatrics 1, 7
Secondary bacterial pneumonia, particularly Staphylococcus aureus, should be vigilantly monitored, especially during influenza outbreaks, according to the Centers for Disease Control and Prevention 5, 6, 8